Updated results from the CLEOPATRA study reveal that a combination of pertuzumab, trastuzumab and chemotherapy confers a survival benefit of 16 months for patients with HER2-positive breast cancer that has spread to other parts of their body. CLEOPATRA was a pivotal phase III study where researchers evaluated the safety and efficacy of pertuzumab, trastuzumb and chemotherapy in 808 patients with previously untreated HER2-positive metastatic breast cancer. HER2-positive ...Saturday 4 October 2014
Research: Pertuzumab Adds 16 Months Survival Benefit to Trastuzumab and Chemo Treatment for HER2-Positive Breast Cancer
Updated results from the CLEOPATRA study reveal that a combination of pertuzumab, trastuzumab and chemotherapy confers a survival benefit of 16 months for patients with HER2-positive breast cancer that has spread to other parts of their body. CLEOPATRA was a pivotal phase III study where researchers evaluated the safety and efficacy of pertuzumab, trastuzumb and chemotherapy in 808 patients with previously untreated HER2-positive metastatic breast cancer. HER2-positive ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment